Founded in 2019 and based in Copenhagen, Denmark, Twelve Bio has developed a CRISPR diagnostic technology that can detect and change any DNA sequence. Their diagnostic test can identify lung cancer from a simple blood test, and they also offer a gene-editing toolbox to target various genetic disorders. By providing tailored and safe molecules, Twelve Bio aims to reduce both the time and expense required for treatment of incurable diseases. In January 2023, the company was acquired by Ensoma, although the terms of the transaction were not disclosed.